Illumina Inc Stock Price, News & Analysis

Illumina (NASDAQ: ILMN) said GeneDx piloted its emerging constellation mapped read technology on 160 DNA samples and reported improved detection of hard-to-map variants versus orthogonal methods. The pilot identified repeat expansions (DMPK), SMN1 events, NCF1-related variants, complex structural variants, and mosaic aneuploidy across blood, buccal, and prenatal samples.

Constellation uses on-flow-cell long molecules with proprietary informatics to resolve homologous and repetitive regions. A commercial product is planned for H1 2026. GeneDx results were presented at ASHG on Oct 15, 2025.

Illumina (NASDAQ: ILMN) will release its third quarter 2025 financial results after market close on Thursday, October 30, 2025.

Management — Jacob Thaysen, PhD, CEO, and Ankur Dhingra, CFO — will host a conference call at 1:30 pm Pacific / 4:30 pm Eastern the same day to discuss financial and operating results. The call will be webcast live via the company's Investor Info site at the provided registration link. Attendees are advised to join at least 10 minutes before the scheduled start. A replay will be posted on Illumina's website and will remain available for at least 30 days after the event.

Illumina (NASDAQ: ILMN) has announced the launch of BioInsight, a new business division focused on developing data assets, software, and AI solutions to accelerate life science discoveries. The initiative will be led by Rami Mehio, who joins the executive leadership team as senior vice president and general manager.

BioInsight will concentrate on four key areas: enabling large-scale genetic data projects, developing software for population-scale data analysis, providing secure data access platforms, and creating AI tools through strategic partnerships. The business aims to leverage the convergence of reduced sequencing costs and advanced AI capabilities to transform biological insights and accelerate drug target discovery.

Predicta Biosciences has successfully raised $23.4 million in an oversubscribed Series A funding round led by Engine Ventures, with participation from notable investors including Illumina Ventures and others. The company also announced the appointment of Brian McKernan as CEO, a three-time biotech founder previously at Fluent BioSciences.

The funding will support the expansion of Predicta's team, CLIA-approved lab infrastructure, and advance the commercialization of GenoPredicta, their first Laboratory Developed Test for multiple myeloma diagnosis. The test, launched in April, can use either peripheral blood or bone marrow to molecularly diagnose individuals at risk for multiple myeloma and inform therapeutic management.

The company aims to develop precision diagnostics for blood cancers and autoimmune diseases, addressing critical gaps in current testing capabilities, particularly for diseases like multiple myeloma where early detection has been challenging.

Illumina (NASDAQ:ILMN) has announced new partnerships with global pharmaceutical companies to develop companion diagnostics (CDx) for the KRAS biomarker using their TruSight™ Oncology Comprehensive genomic profiling test.

The partnerships aim to advance personalized cancer care by helping clinicians match patients with targeted therapies based on genetic mutations. KRAS, one of the most commonly mutated oncogenes in cancer, has historically been difficult to target. The CDx development will enable broader identification of patients who may benefit from targeted therapies, regardless of tumor origin.

The initiative represents a significant advancement in precision oncology, particularly for traditionally difficult-to-treat diseases like pancreatic ductal adenocarcinoma. The genomic profiling capabilities will help improve patient prognostication and treatment decisions through better understanding of KRAS-driven tumor biology.

Illumina (NASDAQ: ILMN) and Nashville Biosciences announced that Alnylam Pharmaceuticals (NASDAQ: ALNY) has joined the Alliance for Genomic Discovery (AGD) as its ninth member. Alnylam, specializing in RNA interference therapeutics, will leverage the AGD's clinical genomic database to accelerate drug target discovery.

The partnership will contribute to expanding the database by adding 31,250 new whole-genomes to the existing 250,000 whole-genome cohort. The AGD dataset, completed in March 2025, combines diverse genomic data with longitudinal clinical phenotyping, utilizing Illumina's DRAGEN™ and Connected Analytics platforms for rapid analysis and insights generation.

Alnylam joins existing members including AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Merck, and Novo Nordisk in this collaborative effort to advance therapeutic discoveries, particularly in autoimmune and neurodegenerative diseases.

Illumina (NASDAQ:ILMN) has launched Illumina Protein Prep, a groundbreaking NGS-based proteomics assay capable of measuring 9,500 unique human protein targets. This launch follows the company's agreement to acquire SomaLogic, strengthening its position in the proteomics market.

The technology has demonstrated significant impact through early access programs, with 30,000 samples processed using the 6K assay and over 6,000 samples with the 9.5K assay. Notable success includes Genomics England's implementation in their 100,000 Genomes Project, which achieved a 7.5% increase in diagnostic yield for rare diseases.

The solution combines Illumina NovaSeq sequencing platforms with DRAGEN Protein Quantification and Connected Multiomics software, enabling researchers to streamline analysis from discovery to therapeutic development. The company has also announced a pilot program with UK Biobank to analyze 50,000 samples using this technology.

Illumina (NASDAQ:ILMN) reported Q2 2025 financial results with revenue of $1.06 billion, marking a 3% decline from Q2 2024. The company achieved a GAAP operating margin of 20.2% and non-GAAP operating margin of 23.8%, with GAAP diluted EPS of $1.49 and non-GAAP diluted EPS of $1.19.

The company has revised its fiscal year 2025 guidance upward, now expecting total company constant currency revenue decline of (2.5%) to (0.5%), improved from previous guidance. Illumina also repurchased 4.5 million shares for $380 million during the quarter and announced plans to acquire SomaLogic from Standard BioTools, with the transaction expected to close in first half of 2026.

Despite challenging research funding conditions, Illumina reported strong performance in clinical segments and margin expansion, leading to increased yearly expectations. The company maintained $1.16 billion in cash and investments and generated $204 million in free cash flow for the quarter.

Illumina (NASDAQ:ILMN) has launched TruSight Oncology 500 version 2 (TSO 500 v2), an enhanced version of its flagship cancer research assay for comprehensive genomic profiling (CGP). The upgraded assay now includes built-in homologous recombination deficiency (HRD) detection at no additional cost, powered by Myriad Genetics' gold-standard Genomic Instability Scoring algorithm.

Key improvements include a streamlined workflow with reduced turnaround time, lower tissue sample requirements, and enhanced sustainability features including 50% less packaging and 70% fewer tubes. The assay enables comprehensive analysis of hundreds of genes and immuno-oncology biomarkers from small tissue samples to support cancer therapy research and clinical trial eligibility assessment.